Hwail Pharm Co Ltd

Hwail Pharm Co Ltd exhibits a strong liquidity position, with a current ratio of 21.74 and cash and equivalents amounting to KRW 61,468,769,170. The company's price-to-book ratio is 3.41, indicating a premium valuation relative to its book value. However, the company reported a net loss of KRW 233,014,530 and an operating loss of KRW 2,226,795,030, suggesting challenges in profitability. The company's return on equity (ROE) and return on assets (ROA) are both negative at -0.0011, indicating poor capital efficiency and asset utilization. These metrics fall below the typical expectations for the Pharmaceuticals industry, where ROE and ROA are generally positive and reflect strong returns on invested capital. Hwail Pharm Co Ltd's revenue is primarily derived from the production and distribution of pharmaceutical raw materials and finished formulations. The company's geographic exposure is concentrated in South Korea, and there is no disclosed information on revenue diversification across regions or segments. The company's growth trajectory appears to be constrained, with no significant revenue growth reported in the latest financial period. The operating cash flow of KRW 11,877,764,350 is positive, but the free cash flow is negative at KRW -2,829,073,940, indicating that capital expenditures are outpacing cash generation. The risk assessment for Hwail Pharm Co Ltd indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and the debt-to-equity ratio is 0.0, suggesting a conservative capital structure. However, the negative operating and net income raise concerns about the company's ability to sustain operations without external financing. Recent financial filings and transcripts do not indicate any significant events or strategic changes that would impact the company's operations or financial performance. The company continues to focus on its core business of pharmaceutical raw materials and finished formulations.